Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells

Nucleic Acids Research

Volumn 34, Issue 2, 2006, Pages 734-744

  Napoli, Sara ^a   Negri, Umberto ^b   Arcamone, Federico ^b   Capobianco, Massimo L ^b   Carbone, Giuseppina M ^a   Catapano, Carlo V ^a  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; MYC PROTEIN; OLIGONUCLEOTIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG CONJUGATION; DRUG SELECTIVITY; DRUG TARGETING; FIBROBLAST; GENE EXPRESSION; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; CELL LINE, TUMOR; DAUNORUBICIN; GENES, MYC; GROWTH INHIBITORS; HUMANS; MALE; OLIGONUCLEOTIDES; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTION, GENETIC;

EID: 32644432553     PISSN: 03051048     EISSN: None     Source Type: Journal    
DOI: 10.1093/nar/gkj473     Document Type: Article

References (32)

1. Goni,J.R., de la Cruz,X. and Orozco,M. (2004) Triplex-forming oligonucleotide target sequences in the human genome. Nucleic Acids Res., 32, 354-360.
2. Praseuth,D., Guieysse,A.L. and Helene,C. (1999) Triple helix formation and the antigene strategy for sequence-specific control of gene expression. Biochim. Biophys. Acta., 1489, 181-206.
3. Casey,B.P. and Glazer,P.M. (2001) Gene targeting via triple-helix formation. Prog. Nucleic Acid Res. Mol. Biol., 67, 163-192.
4. Winters,T.A. (2000) Gene targeted agents: New opportunities for rational drug development. Curr. Opin. Mol. Ther., 2, 670-681.
5. Catapano,C.V., McGuffie,E.M., Pacheco,D. and Carbone,G.M. (2000) Inhibition of gene expression and cell proliferation by triple helix-forming oligonucleotides directed to the c-myc gene. Biochemistry, 39, 5126-5138.
6. McGuffie,E.M., Pacheco,D., Carbone,G.M. and Catapano,C.V. (2000) Antigene and antiproliferative effects of a c-myc-targeting phosphorothioate triple helix-forming oligonucleotide in human leukemia cells. Cancer Res., 60, 3790-3799.
7. Garbesi,A., Bonazzi,S., Zanella,S., Capobianco,M.L., Giannini,G. and Arcamone,F. (1997) Synthesis and binding properties of conjugates between oligodeoxynucleotides and daunorubicin derivatives. Nucleic Acids Res., 25, 2121-2128.
8. Capobianco,M.L., De Champdore,M., Francini,L., Lena,S., Garbesi,A. and Arcamone,F. (2001) New TFO conjugates containing a carminomycinone-derived chromophore. Bioconjug. Chem., 12, 523-528.
9. Carbone,G.M., McGuffie,E., Napoli,S., Flanagan,C.E., Dembech,C., Negri,U., Arcamone,F., Capobianco,M.L. and Catapano,C.V. (2004) DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene. Nucleic Acids Res., 32, 2396-2410.
10. Lown,J.W. (1993) Anthracycline and anthraquinone anticancer agents: current status and recent developments. Pharmacol. Ther., 60, 185-214.
11. Frederick,C.A., Williams,L.D., Ughetto,G., van der Marel,G.A., van Boom,J.H., Rich,A. and Wang,A.H. (1990) Structural comparison of anticancer drug-DNA complexes: Adriamycin and daunomycin. Biochemistry, 29, 2538-2549.
12. Chaires,J.B., Satyanarayana,S., Suh,D., Fokt,I., Przewloka,T. and Priebe,W. (1996) Parsing the free energy of anthracycline antibiotic binding to DNA. Biochemistry, 35, 2047-2053.
13. Capobianco,M.L., De Champdore,M., Arcamone,F., Garbesi,A., Guianvarc'h,D. and Arimondo,P.B. (2005) Improved synthesis of daunomycin conjugates with triplex-forming oligonucleotides. The polypurine tract of HIV-1 as a target. Bioorg. Med. Chem., 13, 3209-3218.
14. Carbone,G.M., Napoli,S., Valentini,A., Cavalli,F., Watson,D.K. and Catapano,C.V. (2004) Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. Nucleic Acids Res., 32, 4358-4367.
15. Spencer,C.A. and Groudine,M. (1991) Control of c-myc regulation in normal and neoplastic cells. Adv. Cancer Res., 56, 1-48.
16. McGuffie,E.M. and Catapano,C.V. (2002) Design of a novel triple helix-forming oligonucleotide directed to the major promoter of the c-myc gene. Nucleic Acids Res., 30, 2701-2709.
17. Dang,C.V. (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell Biol., 19, 1-11.
18. Pelengaris,S., Khan,M. and Evan,G. (2002) c-MYC: More than just a matter of life and death. Nature Rev. Cancer, 2, 764-776.
19. Ellwood-Yen,K., Graeber,T.G., Wongvipat,J., Iruela-Arispe,M.L., Zhang,J., Matusik,R., Thomas,G.V. and Sawyers,C.L. (2003) Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell, 4, 223-238.
20. Bernard,D., Pourtier-Manzanedo,A., Gil,J. and Beach,D.H. (2003) Myc confers androgen-independent prostate cancer cell growth. J. Clin. Invest., 112, 1724-1731.
21. Skorski,T., Perrotti,D., Nieborowska-Skorska,M., Gryaznov,S. and Calabretta,B. (1997) Antileukemia effect of c-myc N3′ → P5′ phosphoramidate antisense oligonucleotides in vivo. Proc. Natl Acad. Sci. USA, 94, 3966-3971.
22. Felsher,D.W. and Bishop,J.M. (1999) Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell, 4, 199-207.
23. Felsher,D.W., Zetterberg,A., Zhu,J., Tlsty,T. and Bishop,J.M. (2000) Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc. Natl Acad. Sci. USA, 97, 10544-10548.
24. Guieysse,A.L., Praseuth,D., Grigoriev,M., Harel-Bellan,A. and Helene,C. (1996) Detection of covalent triplex within human cells. Nucleic Acids Res., 24, 4210-4216.
25. Giovannangeli,C., Diviacco,S., Labrousse,V., Gryaznov,S., Charneau,P. and Helene,C. (1997) Accessibility of nuclear DNA to triplex-forming oligonucleotides: The integrated HIV-1 provirus as a target. Proc. Natl Acad. Sci. USA, 94, 79-84.
26. Benimetskaya,L., Berton,M., Kolbanovsky,A., Benimetsky,S. and Stein,C.A. (1997) Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-kappaB p65) 'antisense' oligodeoxynucleotide. Nucleic Acids Res., 25, 2648-2656.
27. Bates,P.J., Kahlon,J.B., Thomas,S.D., Trent,J.O. and Miller,D.M. (1999) Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J. Biol. Chem., 274, 26369-26377.
28. Cogoi,S., Quadrifoglio,F. and Xodo,L.E. (2004) G-rich oligonucleotide inhibits the binding of a nuclear protein to the Ki-ras promoter and strongly reduces cell growth in human carcinoma pancreatic cells. Biochemistry, 43, 2512-2523.
29. Liu,L.F. (1989) DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58, 351-375.
30. Feinstein,E., Canaani,E. and Weiner,L.M. (1993) Dependence of nucleic acid degradation on in situ free-radical production by adriamycin. Biochemistry, 32, 13156-13161.
31. Asseline,U., Delarue,M., Lancelot,G., Toulme,F., Thuong,N.T., Montenay-Garestier,T. and Helene,C. (1984) Nucleic acid-binding molecules with high affinity and base sequence specificity: intercalating agents covalently linked to oligodeoxynucleotides. Proc. Natl Acad. Sci. USA, 81, 3297-3301.
32. Sun,J.S., Francois,J.C., Montenay-Garestier,T., Saison-Behmoaras,T., Roig,V., Thuong,N.T. and Helene,C. (1989) Sequence-specific intercalating agents: Intercalation at specific sequences on duplex DNA via major groove recognition by oligonucleotide-intercalator conjugates. Proc. Natl Acad. Sci. USA, 86, 9198-9202.